{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224101","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2026-05-14T20:19:13+00:00","discovered_at":"2026-05-14T20:20:00.231943+00:00","generated_at":"2026-05-14T20:45:56.616394+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cue Biopharma Q1 net loss $5.2M; appoints new CEO, $30M private placement, CUE-221 license","bullets":["Net loss $5.2M ($1.08 EPS) vs $12.3M loss in Q1 2025; revenue $5.7M from Boehringer collaboration.","Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO and Board Director.","Completed $30M private placement (pre-funded and common warrants); received $7.5M milestone from Boehringer.","Exclusive license for CUE-221 (Phase 2 anti-IgE) from Ascendant Health; IND amendment for food allergy expected H2 2026.","Cash $16.4M at Mar 31, 2026; subsequent $30M private placement extends runway for clinical milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224101","json":"https://secwatch.observer/filing/0001193125-26-224101.json","markdown":"https://secwatch.observer/filing/0001193125-26-224101.md","text":"https://secwatch.observer/filing/0001193125-26-224101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526224101/0001193125-26-224101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526224101/cue-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:45:56.616394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6fc8bf73664b68c232068151ae6cbe6990ccdf6","claim":"Cue Biopharma, Inc. reported the quarter ended March 31, 2026 results: revenue $5.7 million, net income Net loss ... $5.2 million, EPS $(1.08) per common share – basic and diluted.","evidence_excerpt":"to the FDA in the second half of 2026 • Phase 1 first-in-human study expected to be initiated by year-end 2026. First Quarter 2026 Financial Results First quarter revenue was $5.7 million compared to $0.4 million in the first quarter of 2025. The revenue earned during the three months ended March 31, 2026 was related to the Boehringer Ingelheim collaboration and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526224101/0001193125-26-224101-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$5.7 million"},{"label":"Net income","value":"Net loss ... $5.2 million"},{"label":"EPS","value":"$(1.08) per common share – basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}